Interestingly, along with the identification of tumorigenic pathways (e.g., p53 and Hippo signaling) and metabolic/structural events associated with the cell cycle (Table S4), we also found immune-related terms implying the existence of a complex immune scenery in NSCLC, possibly having major implications in setting up protocols for immune-based precision medicine strategies [61]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.